Table 3.
Cochrane risk of bias assessment.
| Study | Agent | Random sequence generation | Allocation concealment | Selective reporting | Other sources of bias | Blinding (outcome) | Blinding (participants and personnel) | Incomplete outcome data |
|---|---|---|---|---|---|---|---|---|
| Ogawa et al. (12) | Ebselen | Low | Unclear | Unclear | Low | Low | Unclear | Low |
| Clark et al. (13) | Nalmefene | Unclear | Low | High | High | Unclear | Low | Unclear |
| Sacco et al. (14) | Gavestinel | Low | Low | Unclear | Low | Low | Low | Unclear |
| Lyden et al. (15) | Clomethiazole | Low | Low | Unclear | High | Unclear | Low | Low |
| Krams et al. (16) | UK 279,276 | Low | Low | Unclear | Unclear | Low | Low | Low |
| Amaro et al. (17) | Uric acid | Low | Unclear | Unclear | Unclear | Low | Unclear | Unclear |
| Diener et al. (18) | NXY-059 | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Ehrenreich et al. (19) | Erythropoietin | Low | Low | Unclear | Low | Low | Low | Low |
| Teal et al. (20) | Repinotan | Unclear | Unclear | Unclear | Low | Unclear | Low | Unclear |
| Hemmen et al. (21) | Hypothermia | Low | High | Low | Low | Unclear | High | Unclear |
| Heiss et al. (22) | Cerebrolysin | Unclear | Unclear | Unclear | High | Low | Unclear | High |
| Ginsberg et al. (23) | Albumin | Low | Low | Unclear | Low | Low | Low | High |
| Lang et al. (24) | Cerebrolysin | Low | Unclear | Unclear | Unclear | Unclear | Low | High |
| Hougaard et al. (25) | Remote ischemic perconditioning | Low | Unclear | Unclear | Unclear | Low | High | High |
| Saver et al. (26) | Magnesium | Low | Unclear | Unclear | Low | Low | Low | Low |
| Woodhouse et al. (27) | Transdermal Glyceryl Trinitrate | Low | Low | High | Low | Low | Low | Low |
| Montaner et al. (28) | Simvastatin | Low | Low | Unclear | Unclear | Low | Low | Low |
| Wahlgren et al. (29) | Imatinib | Low | Unclear | Unclear | Unclear | Unclear | Unclear | Low |
| Wang et al. (30) | Epigallocatechin gallate | Low | Unclear | Unclear | Low | Low | Low | Unclear |
| Chamorro et al. (31) | Uric acid | Low | Low | Unclear | Low | Low | Low | Low |
| Lyden et al. (32) | 3K3A-APC | Low | Unclear | Low | Unclear | Low | Low | Low |
| Culp et al. (33) | Dodecafluoropentane | Unclear | Low | Unclear | Unclear | Low | Low | Unclear |
| Kim et al. (34) | Otaplimastat | Low | Low | Unclear | Low | Unclear | Low | Low |
| Pico et al. (35) | Remote ischemic preconditioning | Low | Low | Unclear | Low | Unclear | Low | Low |
| Hill et al. (36) | Nerinetide | Low | Low | Unclear | Low | Low | Low | Low |
| An et al. (37) | Remote ischemic perconditioning | Low | High | Unclear | Unclear | Unclear | High | Unclear |
| Modrau et al. (38) | Theophylline | Low | Unclear | Unclear | High | Unclear | Unclear | Unclear |
| He et al. (39) | Remote ischemic perconditioning | Low | Unclear | Unclear | Unclear | Low | Unclear | Low |
| Cheng et al. (40) | Normobaric oxygen | Low | Low | Unclear | Unclear | Low | Low | Low |
| Pruvost-Robieux et al. (41) | Transcranial stimulation | Low | Low | Low | Low | Unclear | Low | Low |